Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Overview
Abbott Laboratories (ABT) is a globally recognized, diversified healthcare company committed to improving lives at every stage. The company is entrenched in the design, development, and marketing of an extensive portfolio that spans medical devices, diagnostic equipment, nutritional products, and branded generic drugs. Its advanced and innovative technologies in areas such as diabetes care, cardiovascular treatment, and advanced electrophysiology are integrated with a deep understanding of clinical needs and patient outcomes. Abbott leverages decades of research and development to address critical health challenges worldwide, maintaining a strong emphasis on quality, reliability, and accessibility.
Core Business Segments
Abbott's diversified business model is structured around four primary segments:
- Medical Devices: Abbott manufactures an array of devices including cardiovascular implants, pacemakers, stents, and electrophysiology tools. This segment emphasizes minimally invasive technologies and groundbreaking approaches like pulsed field ablation and advanced cardiac mapping systems.
- Diagnostics: With an expansive portfolio of diagnostic systems and point-of-care devices, Abbott provides essential tools for rapid, accurate testing in infectious diseases, chronic conditions, and routine health screening, bolstered by its world-leading assay technologies.
- Nutritional Products: The company produces both adult and pediatric nutritional products, including infant formulas backed by almost a century of nutritional science. Its brands are designed to meet diverse dietary needs and preferences while adhering to stringent quality standards.
- Branded Generic Medicines: Abbott also offers a range of branded generic products, ensuring broader accessibility and supporting treatment options in emerging markets.
Innovation and Industry Leadership
Abbott’s commitment to innovation is evident across all its divisions. The company has introduced market-disruptive technologies like continuous glucose monitoring systems that empower individuals with data-driven insights, significantly enhancing diabetes management. Additionally, its advancements in structural heart interventions and neuromodulation demonstrate a robust integration of clinical research, sophisticated diagnostics, and cutting-edge device engineering.
Global Reach and Operational Excellence
With a significant percentage of its sales generated internationally, Abbott enjoys a strong global presence. Its strategic partnerships and collaborations allow the company to extend its technological expertise and clinical insights around the world. This global reach not only diversifies revenue streams but also reinforces Abbott's commitment to addressing the healthcare challenges in different markets with tailored solutions.
Commitment to Quality and Research
Quality, precision, and reliability are fundamental to Abbott's operations. The company invests substantially in research and clinical trials, ensuring that each product meets high standards of safety and efficacy. By integrating interdisciplinary expertise from clinical, engineering, and regulatory domains, Abbott continuously refines its products and solutions to meet the evolving needs of healthcare providers and patients.
Conclusion
Overall, Abbott Laboratories stands as a pillar of innovation and reliability within the global healthcare landscape. Its multi-faceted approach—spanning medical devices, diagnostics, nutritional products, and branded generics—ensures that it remains at the forefront of addressing complex healthcare challenges. For investors and industry analysts seeking comprehensive insights into Abbott’s business model and its contributions to modern healthcare, the company exemplifies excellence in research, operational efficiency, and global market integration.
Abbott (NYSE: ABT) announced positive two-year data from its TRILUMINATE™ Pivotal trial for the TriClip™ transcatheter edge-to-edge repair (TEER) system, designed to treat tricuspid regurgitation (TR). The results, presented at ACC.25 and published in Circulation, demonstrate significant improvements over medical therapy.
Key findings after two years include:
- Significant reduction in heart failure hospitalizations (0.19 vs. 0.26 events/patient-year) in the treatment group
- 84% of TriClip patients achieved moderate or less TR grade versus 21% in control group
- Patients showed over 15-point improvement in quality of life scores (KCCQ)
- More than half of control group patients (142 of 241) crossed over to receive TriClip therapy, showing similar improvements
The data confirms TriClip as a safe and effective treatment option for TR patients who are not suitable for open-heart surgery, offering sustained benefits in reducing valve leakage and improving quality of life.
Abbott (NYSE: ABT) has received CE Mark approval in Europe for its Volt™ PFA System, designed to treat atrial fibrillation (AFib). The system has begun commercial cases in the EU following strong clinical trial results showing 99.1% success rate in pulmonary vein isolation.
The Volt PFA System offers a single-catheter approach for mapping, pacing, and ablating, integrating with Abbott's EnSite™ X EP system. Key features include simplified workflow, efficient energy delivery through a proprietary balloon-in-basket design, and procedural flexibility allowing for light sedation or general anesthesia.
The approval comes as approximately 8 million Europeans over 65 live with AFib, a number expected to double in 30 years. The system is currently under evaluation in the VOLT-AF IDE Study with nearly 400 patients enrolled, with 12-month follow-up expected later this year.
Abbott (NYSE: ABT) has scheduled its first-quarter 2025 financial results announcement for Wednesday, April 16, before market opening. The company will host a live webcast earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. An archived version of the call will be made available later the same day.
Abbott (NYSE: ABT) has received FDA approval for an investigational device exemption (IDE) to evaluate its Coronary Intravascular Lithotripsy (IVL) System in treating severe calcification in coronary arteries before stenting. The TECTONIC trial will enroll up to 335 people across 47 U.S. sites.
The technology uses high-energy sound pressure waves to fracture calcium within artery walls, potentially improving vessel expansion and stent placement. This development addresses Coronary Artery Disease (CAD), which affects over 20 million U.S. adults and is America's leading cause of death.
Abbott's IVL system complements their existing vascular portfolio, which includes optical coherence tomography (OCT) imaging technology for calcium detection. The system aims to overcome limitations of current treatment approaches like cutting balloons and atherectomy technology.
Cadrenal Therapeutics (NASDAQ: CVKD) reported its full year 2024 results and updates on tecarfarin development. The company secured a collaboration with Abbott for the TECH-LVAD Phase 3 trial and received additional FDA guidance through a Type D meeting.
Key financial highlights include:
- Net loss of $10.7M in 2024 vs $8.4M in 2023
- R&D expenses of $4.2M vs $4.1M in 2023
- G&A expenses increased to $6.8M from $3.5M
- Cash position of $10.0M as of December 31, 2024
- Raised $9.8M through ATM facility ($5.1M) and warrant exercises ($4.7M)
Notable achievements include FDA Orphan Drug Designation for tecarfarin in mechanical circulatory support devices, appointment of new executive leadership, and completion of manufacturing readiness for Phase 3 trial materials.
Cagent Vascular has appointed Paul Wilson as Chief Commercial Officer (CCO) to lead the company's commercial strategy. Wilson, who previously held senior leadership positions at Teleflex (TFX) and Abbott, will oversee sales, marketing, clinical programming, and business development initiatives.
The company's proprietary serration balloon technology, including the FDA-cleared Serranator® and Serranator SL-PRO™ PTA Serration Balloon Catheters, uses stainless steel micro-serration technology for vessel dilation in endovascular interventions. The technology delivers 1,000x more point force compared to traditional balloon angioplasty, creating linear, interrupted scoring during slow-and-low balloon inflation to optimize vessel preparation and enhance arterial expansion in peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI).
Cadrenal Therapeutics (CVKD) has announced a significant collaboration agreement with Abbott (ABT) to support their pivotal TECH-LVAD trial, evaluating tecarfarin in patients with Left Ventricular Assist Devices (LVADs).
The collaboration focuses on testing tecarfarin, a new oral Vitamin K antagonist (VKA), with Abbott's HeartMate 3™ LVAD, which is currently the only advanced mechanical circulatory support device available in the United States for patients with advanced heart failure.
Under the agreement, Abbott will provide support in:
- Trial design
- Site identification
- Trial awareness
- HeartMate 3™ expertise
The LVAD market, valued at $1.1 billion in 2023, is projected to reach $2.4 billion by 2032, according to Business Research Insights.
Abbott (NYSE: ABT) has announced its 405th consecutive quarterly dividend of 59 cents per share, continuing a remarkable streak that began in 1924. The dividend will be payable on May 15, 2025, to shareholders of record as of April 15, 2025.
The company has demonstrated exceptional consistency in shareholder returns, having increased its dividend payout for 53 consecutive years. This achievement has earned Abbott a position in the prestigious S&P 500 Dividend Aristocrats Index, which recognizes companies that have raised their dividends annually for at least 25 consecutive years.
Abbott has released new survey findings and a film highlighting how misconceptions and stigma affect people living with diabetes. The survey of over 2,600 people across eight countries revealed concerning statistics: 40% have missed doctor's appointments due to shame, nearly 70% believe there is stigma associated with their condition, and 85% have witnessed inaccurate diabetes portrayals in media.
The study showed that almost 25% avoided sharing their diagnosis with family or friends, while biometric testing indicated 40% of individuals had elevated physiological responses to stigmatizing statements. Notably, questions about food choices triggered the strongest stress responses.
Abbott's new 'Above the Bias' initiative aims to promote understanding of diabetes from patients' perspectives. The survey also found that 70% of respondents reported that supportive comments significantly boost their motivation to manage their condition.
Abbott (ABT) reported strong Q4 2024 results with sales of $11.0 billion, up 7.2% on a reported basis and 10.1% organic growth excluding COVID-19 testing. Full-year 2024 sales reached $42.0 billion, increasing 4.6% on a reported basis and 9.6% organic growth excluding COVID-19 testing.
The company achieved the upper end of its initial 2024 guidance ranges for both organic sales growth and adjusted earnings per share. Q4 2024 GAAP diluted EPS was $5.27, while adjusted diluted EPS was $1.34. Full-year 2024 GAAP diluted EPS was $7.64, with adjusted EPS at $4.67.
Looking ahead, Abbott projects full-year 2025 organic sales growth of 7.5% to 8.5%, with adjusted operating margin expected to be 23.5% to 24.0%. The company forecasts full-year 2025 adjusted diluted EPS of $5.05 to $5.25, representing double-digit growth at the midpoint.